Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Nanoparticles Can Enhance Cisplatin in Chemotherapy

July 8, 2014 2:19 pm | News | Comments

Researchers have developed a new formulation of cisplatin, a common chemotherapy drug, that significantly increases the drug's ability to target and destroy cancerous cells. Read more...                   


Newly Discovered Compounds Could Affect Circadian Rhythm

July 8, 2014 2:08 pm | News | Comments

Scientists have discovered a surprising new role for a pair of compounds that have the potential to alter circadian rhythm. At least one of these compounds could be developed to uncover new therapeutic approaches to a range of disorders. Read more...


AbbVie Raises Bid for Shire to $51.3B

July 8, 2014 1:51 pm | News | Comments

U.S. drugmaker AbbVie has boosted its offer for Shire by 11 percent to about $51.3 billion, hoping it will be enough to pique the interest of its British counterpart. Read more...                     


AstraZeneca, Max Planck Institute Create Satellite Chemistry Unit

July 8, 2014 10:46 am | News | Comments

AstraZeneca announced an agreement with the Max Planck Institute of Molecular Physiology, Germany, to establish a "satellite unit" in cardiovascular and metabolic disease (CVMD), linked to AstraZeneca’s CVMD Innovative Medicines unit in Mölndal, Sweden, to study new modalities chemistry. Read more...


FDA Accepts NDA for Sanofi's Basal Insulin

July 8, 2014 10:40 am | News | Comments

Sanofi announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), an investigational basal insulin, formerly abbreviated as "U300." Read more...


Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hep C Treatment

July 8, 2014 10:34 am | News | Comments

Bristol-Myers Squibb announced that the Japanese Ministry of Health, Labor and Welfare has approved Daklinza, a potent, pan-genotypic NS5A replication complex inhibitor, and Sunvepra, a NS3/4A protease inhibitor, providing a new treatment that can lead to cure for many patients in Japan who currently have no treatment options. Read more...


Merck Serono Funds Scientific Innovation

July 8, 2014 10:22 am | News | Comments

Merck Serono, the biopharmaceutical division of Merck, announced the launch of Merck Global Grants – a program that underscores the company’s commitment to funding scientific innovation and independent medical education around the world. Read more...


Researchers Block Memories in Rats, Reduce Drug-Seeking

July 8, 2014 10:15 am | News | Comments

In substance addiction, drug-associated memories are known to powerfully compel craving and drug seeking behavior. Research by Prof. Barry Everitt at the University of Cambridge, UK, indicates that disrupting the brain's memory pathways might point towards future addiction therapy approaches. Read more...


Pershing Square Names Allergan Board Candidates

July 8, 2014 10:10 am | News | Comments

Investment firm Pershing Square Capital Management on Monday identified its six nominees for spots on the board of Allergan as it tries to buy the Botox maker by holding a special meeting where Allergan shareholders can have a say in the buyout bid and on the Irvine, California-based company's direction. Read more...


Personalized Immunotherapy for Leukemia Named Breakthrough Therapy

July 7, 2014 2:36 pm | News | Comments

A University-developed personalized immunotherapy was awarded the FDA's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia. The therapy, known as CTL019, is the first personalized cellular therapy for the treatment of cancer to receive this classification. Read more...


NIH Awards SBIR Grant for Epigenetic Database

July 7, 2014 2:25 pm | News | Comments

Reaction Biology Corp. (RBC) announced that it has been awarded a Phase 1 SBIR grant from the National Center for Advancing Translational Sciences to create a database of epigenetic drug interactions. Read more...           


Hepatocellular Carcinoma Drug Gets Orphan Designation

July 7, 2014 2:13 pm | News | Comments

CASI Pharmaceuticals Inc. announced that its orally-active, Aurora A/angiogenic kinase inhibitor, ENMD-2076, has received Orphan Drug designation from the FDA for the treatment of hepatocellular carcinoma. Read more...         


Animal Vaccines Should Guide Malaria Research

July 7, 2014 2:07 pm | News | Comments

Research into vaccines for malaria in humans should be guided by the success shown in producing effective vaccines for malaria-like diseases in animals, according to a new study. Read more...                  


99% of Alzheimer's Drug Trials Fail, Study Says

July 7, 2014 1:53 pm | News | Comments

Researchers have conducted the first-ever analysis of clinical trials for Alzheimer’s disease (AD), revealing an urgent need to increase the number of agents entering the AD drug development pipeline and progressing successfully towards new therapy treatments. Read more...


Chronic Pain Drug Pushes Through Phase 3

July 7, 2014 12:47 pm | News | Comments

Endo Pharmaceuticals Inc. and BioDelivery Sciences International Inc. announced positive top-line results from its pivotal Phase 3 efficacy study of BEMA buprenorphine in opioid-experienced patients. Read more...            



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.